CSIMarket Company Name, Ticker, Suppliers, else..
 
Sensei Biotherapeutics Inc   (NASDAQ: SNSE)
 
Price: $9.0000 $0.43 5.018%
Day's High: $9.23 Week Perf: -7.41 %
Day's Low: $ 7.58 30 Day Perf: -5.91 %
Volume (M): 42 52 Wk High: $ 18.35
Volume (M$): $ 375 52 Wk Avg: $8.66
Open: $8.06 52 Wk Low: $5.00



 Market Capitalization (Millions $) 11
 Shares Outstanding (Millions) 1
 Employees 14
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -24
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 0

Sensei Biotherapeutics Inc
Sensei Biotherapeutics Inc is a biopharmaceutical company that focuses on developing precision immuno-oncology therapies. The company harnesses the power of the immune system to target specific tumor antigens, with the goal of improving outcomes for cancer patients. Sensei Biotherapeutics utilizes its proprietary ImmunoPhage platform to design and develop personalized vaccines and cell therapies. The company's approach involves engineering bacteriophage-based delivery vehicles to deliver tumor antigens directly to immune cells, promoting a targeted immune response against cancer cells. Sensei Biotherapeutics aims to advance the field of immuno-oncology by leveraging its innovative platform and expertise in tumor-specific immunology.


   Company Address: 1405 Research Blvd Rockville 20850 MD
   Company Phone Number: 243-8000   Stock Exchange / Ticker: NASDAQ SNSE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADCT        27.05% 
MDGL   -1.03%    
NRIX        5.42% 
RYTM        12.45% 
SUPN        1.82% 
ZYME   -6.56%    
• View Complete Report
   



Clinical Study

Unveiling Solnerstotugs Potential in PD-(L)1 Resistant Tumors Insights from the ESMO Congress 2025

Published Mon, Oct 20 2025 10:28 AM UTC

: The treatment landscape for cancer, specifically resistant tumors, has taken a transformative turn with the advent of novel therapeutic agents. This article analyzes the promising results from Sensei Biotherapeutics, Inc. s recent clinical data presented at the ESMO Congress 2025, highlighting the efficacy of the conditionally active monoclonal antibody, solnerstotug (form...
Product Service News

Sensei Biotherapeutics Implements Reverse Stock Split Amidst Competitive Revenue Decline

Published Fri, Jun 13 2025 12:26 PM UTC

On June 13, 2025, Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology firm focused on pioneering therapeutics for cancer treatment, announced a significant corporate action: a 1-for-20 reverse stock split of its issued and outstanding shares of common stock. This move, set to take effect at 5:00 p.m. Eastern Time on June 16, 2025, follows approval fro...
Product Service News

This article provides an examination of recent updates from Sensei Biotherapeutics regarding th...

Published Wed, Jan 8 2025 12:57 PM UTC

Sensei Biotherapeutics Progresses with SNS-101 Clinical Development: Anticipates Full Enrollment by Q1 2025 : This article provides an examination of recent updates from Sensei Biotherapeutics regarding the clinical development of their monoclonal antibody, SNS-101. The analysis includes milestones achieved, strategic plans, and future expectations as outlined in their re...
Clinical Study

Sensei Biotherapeutics, a leading biotechnology company focused on the development of immunotherapies, has recently presented encouraging clinical data from its Phase 1 dose escalation study of SNS-101. The study demonstrated initial signs of promising clinical activity, marking a significant milestone in the quest for effective cancer treatments.SNS-101, a novel ca...

Published Thu, May 23 2024 9:10 PM UTC

NEWS HEADLINE: Sensei Biotherapeutics SNS-101 Shows Promising Clinical Activity in Phase 1 Dose Escalation StudySensei Biotherapeutics, a leading biotechnology company focused on the development of immunotherapies, has recently presented encouraging clinical data from its Phase 1 dose escalation study of SNS-101. The study demonstrated initial signs of promising clinical ac...
Product Service News

Exploring New Horizons: Sensei Biotherapeutics Unravels Topline Clinical Data at the 2024 ASCO Annual Meeting

Published Wed, Apr 24 2024 8:05 PM UTC

In the rapidly evolving sphere of immuno-oncology, Sensei Biotherapeutics, Inc., a clinical-stage company, has emerged as a significant player. Raising the bar further, Sensei recently announced that the company is set to present the topline clinical data from its innovative Phase 1/2 trial study of SNS-101, a potential breakthrough in cancer therapeutics. This highly antici...









Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2025 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.